Hemispherx Biopharma Stockholders Approve Reverse Stock Split

by Barry101 | May 31, 2019 | Press Release

OCALA, Fla., May 31, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, today announced that its stockholders...

Hemispherx Reports 2019 First Quarter Financial Results

by Barry101 | May 16, 2019 | Press Release

OCALA Fla., May 16, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announces financial results for the...

Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center

by Barry101 | May 13, 2019 | Press Release

OCALA, Fla., May 13, 2019 — Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announced progress toward the opening...

Hemispherx Biopharma’s CEO to Attend BioFlorida Inc.’s 2019 Celebration of Biotechnology

by Barry101 | May 8, 2019 | Press Release

OCALA, Fla., May 08, 2019 — (NYSE American: HEB) – Hemispherx Biopharma Inc.’s CEO Thomas K. Equels will be attending the 2019 Celebration of Biotechnology where he’ll meet with investors and industry representatives to discuss the...

Hemispherx Links Stanford's ME/CFS Diagnostic to a Potential Path Forward for Ampligen Commercialization

by Barry101 | May 6, 2019 | Press Release

OCALA, Fla., May 06, 2019 — Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases – and whose product portfolio...